Search Results - "Hao, Chunfang"

Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients by Wang, Shuling, Li, Weidong, Li, Shuai, Liu, Xiaodong, Zhang, Li, Hao, Chunfang, Meng, Wenjing, Zhao, Weipeng, Tong, Zhongsheng

“…Background. Breast carcinoma is the most common malignancy in women. Gastrointestinal metastasis is rarely found or diagnosed in patients with breast cancer…”
Get full text

Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer by Hao, Chunfang, Bai, Xuedong, Zhang, Jie, Meng, Wenjing, Tong, Zhongsheng

“…Objective Our study evaluated the renal safety of abemaciclib plus endocrine therapy (ET) with bisphosphonate as a treatment option for hormone receptor…”
Get full text

The changes of subtype markers between first and second primary breast cancers by Li, Chenyang, Lyu, Zhangyan, Wang, Zhipeng, Hao, Chunfang, Huang, Yubei, Song, Fengju

“…Background Previous studies investigated the changes of subtype markers [estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor…”
Get full text

Cytokine levels and pathological characteristics of a patient with severe coronavirus disease 2019: a case report by Kang, Kai, Gao, Yang, Zhao, Mingyan, Fei, Dongsheng, Ye, Ming, Gao, Yan, Yang, Wei, Wang, Changsong, Liu, Haitao, Chang, Guangping, Kang, Xianxin, Luo, Yunpeng, Du, Xue, Qi, Jiping, Tian, Lin, Zhou, Min, Hao, Chunfang, Yu, Kaijiang

“…Laboratory tests revealed that the IL-6 and IL-10 levels were increased (345.51 and 44.77 pg/mL, respectively). [...]CD4+ T cell count was 147 cells/μL, and…”
Get full text

Establishing extended pluripotent stem cells from human urine cells by Hao, Chunfang, Chu, Shilong, Quan, Xiongzhi, Zhou, Tiancheng, Shi, Junjie, Huang, Xiaofen, Wu, Guangming, Tortorella, Micky Daniel, Pei, Duanqing

“…Extended pluripotent stem cells (EPSCs) can contribute to both embryonic and trophectoderm-derived extraembryonic tissues. Therefore, EPSCs have great…”
Get full text

Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2‐low and HER2‐zero breast cancer among Chinese females by Zheng, Lu, Zhang, Yunmeng, Wang, Zhipeng, Wang, Huan, Hao, Chunfang, Li, Chenyang, Zhao, Yanrui, Lyu, Zhangyan, Song, Fangfang, Chen, Kexin, Huang, Yubei, Song, Fengju

“…Background Traditional human epidermal growth factor receptor 2 (HER2)‐negative breast cancer (BC) is recommended to be divided into HER2‐low and HER2‐zero…”
Get full text

Gene Mutations Associated With Clinical Characteristics in the Tumors of Patients With Breast Cancer by Hao, Chunfang, Wang, Chen, Lu, Ning, Zhao, Weipeng, Li, Shufen, Zhang, Li, Meng, Wenjing, Wang, Shuling, Tong, Zhongsheng, Zeng, Yanwu, Lu, Leilei

“…Clinical characteristics including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) are important biomarkers in…”
Get full text

Stimulatory Cross-talk between NFAT3 and Estrogen Receptor in Breast Cancer Cells by Zhang, Hao, Xie, Xiangyang, Zhu, Xudong, Zhu, Jianhua, Hao, Chunfang, Lu, Qiujun, Ding, Lihua, Liu, Yufei, Zhou, Lei, Liu, Yaling, Huang, Cuifen, Wen, Chungen, Ye, Qinong

“…Estrogen receptors (ERα and ERβ) are ligand-regulated transcription factors that play critical roles in the development and progression of breast cancer by…”
Get full text

SNX16 negatively regulates the migration and tumorigenesis of MCF-7 cells by Zhang, Leilei, Qin, Dajiang, Hao, Chunfang, Shu, Xiaodong, Pei, Duanqing

“…Sorting nexins are a large family of proteins that are associated with various components of the endosome system and they play many roles in processes such as…”
Get full text

PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer by Hao, Chunfang, Wei, Yunchu, Meng, Wenjing, Zhang, Jie, Yang, Xiaonan

Get full text

CDK4/6 inhibitors combined with fulvestrant for HR+/HER2− advanced breast cancer by Zhang, Jie, Hao, Chunfang

Get full text

T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study by Zhang, Ruyan, Li, Huiping, Zhang, Pin, Hao, Chunfang, Zhao, Wenhui, Mo, Xueli

“…e13026 Background: In the pivotal EMILIA and THRESA study, the proportion of Chinese patients in the clinical trials was very low (17% of Asian patients, 87…”
Get full text

Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial by Hao, Chunfang, Qi, Xiaowei, Shi, Yehui, Tong, Zhongsheng, Zhang, Jie, Meng, Wenjing, Yang, Xiaonan

“…e13005 Background: The Chinese Society of Clinical Oncology Guidelines recommended the pyrotinib plus capecitabine regimen as the standard of care for patients…”
Get full text

Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial by Yan, Min, Ouyang, Quchang, Sun, Tao, Niu, Limin, Yang, Jin, Li, Li, Song, Yuhua, Hao, Chunfang, Chen, Zhanhong, Orlandi, Armando, Ishii, Naohiro, Takabe, Kazuaki, Franceschini, Gianluca, Ricci, Francesco, Verschraegen, Claire, Liu, Zhenzhen, Zhang, Mengwei, Lv, Huimin, Liu, Liping, Yang, Xiaohong, Xiao, Huawu, Gao, Zhichao, Li, Xiaorui, Dong, Fangyuan, Chen, Xiuchun, Qiao, Jianghua, Zhang, Guifang

“…Patients with HER2-positive metastatic breast cancer have a high risk of developing brain metastases. Efficacious treatment options are scarce. We investigated…”
Get full text

Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2-positive advanced breast cancer who had failed prior trastuzumab-based therapy: A single-center, single-arm, prospective phase 2 study by Hao, Chunfang, Wang, Xu, Shi, Yehui, Tong, Zhongsheng, Li, Shufen, Liu, Xiaodong, Zhang, Lan

“…1033 Background: In 15% to 30% of breast cancers, human epidermal growth factor receptor 2 (HER2) is overexpressed, this is related to aggressive disease and…”
Get full text

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial by Yan, Min, Ouyang, Quchang, Sun, Tao, Niu, Limin, Yang, Jin, Li, Li, Song, Yuhua, Hao, Chunfang, Chen, Zhanhong

“…1048 Background: HER2-positive metastatic breast cancer has a high risk of brain metastases, leading to poor survival. Our phase 2 PERMEATE trial (NCT03691051)…”
Get full text

A phase 3, multicenter, open, randomized controlled clinical study of gemcitabine plus capecitabine versus gemcitabine plus carboplatin in the first-line treatment for advanced triple-negative breast cancer by Liu, Xiaodong, Zhao, Weipeng, Jia, Yongsheng, Shi, Yehui, Wang, Xu, Li, Shufen, Wang, Chen, Hao, Chunfang, Tong, Zhongsheng

“…1077 Background: Gemcitabine plus capecitabine (GX) regimen is still lack of phase Ⅲ clinical trial evidence for the first-line treatment of advanced…”
Get full text

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer by Jia, Yan, Song, Yueshuai, Dong, Guolei, Hao, Chunfang, Zhao, Weipeng, Li, Shufen, Tong, Zhongsheng

“…Breast cancer is one of the most common malignant cancers affecting females. Estrogen receptor (ER)-positive breast cancer is responsive to endocrine therapy…”
Get full text

Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study by Yan, Min, Ouyang, Quchang, Sun, Tao, Niu, Limin, Yang, Jin, Li, Li, Song, Yuhua, Hao, Chunfang, Chen, Zhanhong

“…Abstract only 1037 Background: HER2-positive metastatic breast cancer (BC) has a high risk of brain metastases (BM), leading to poor survival. Small molecule…”
Get full text

Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer After Trastuzumab Failure (PROVE): A Prospective Phase 2 Study by Hao, Chunfang, Wang, Xu, Shi, Yehui, Tong, Zhongsheng, Li, Shufen, Liu, Xiaodong, Zhang, Lan, Zhang, Jie, Meng, Wenjing, Zhang, Li

“…Approximately 50-74% of patients with metastatic HER2-positive breast cancer do not respond to trastuzumab, with 75% of treated patients experiencing disease…”
Get full text